Products for Research Use Only

Vonafexor

CAT: 0804-HY-109197-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-109197-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Vonafexor (EYP001) is an orally active, non-steroidal and selective FXR agonist. Vonafexor shows significant HBsAg reduction when combined with Peg-IFNα. Vonafexor can be used for anti-HBV research[1][2].
CAS Number
1192171-69-9
Product Name Alternative
EYP001
UNSPSC
12352005
Hazard Statement
H302-H319-H332-H372-H400
Target
FXR; HBV
Type
Reference compound
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/vonafexor.html
Purity
99.32
Solubility
DMSO : 83.33 mg/mL (ultrasonic)
Smiles
O=C(C1=CC2=C(Cl)C(N3CCN(S(=O)(C4=C(Cl)C=CC=C4Cl)=O)CC3)=CC=C2O1)O
Molecular Formula
C19H15Cl3N2O5S
Molecular Weight
489.76
Precautions
P260-P261-P264-P270-P271-P273-P280-P304+P340-P305+P351+P338-P330-P391-P501
References & Citations
[1]Joly S, et al. The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells. J Hepatol 66 (1) :S690.|[2]Fiorucci S, et al. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH) [published online ahead of print, 2020 Jun 19]. Expert Opin Investig Drugs. 2020;1-10.|[3]Erken R, et al. Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study. J Viral Hepat. 2021 Dec;28 (12) :1690-1698.|[4]Hui RW, et al. Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials. Expert Opin Emerg Drugs. 2022 Jun;27 (2) :127-140.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2